Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Aug 2;8(8):CD011312.
doi: 10.1002/14651858.CD011312.pub3.

Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease

Johanna Hummel  1 , Gerta Rücker, Brigitte Stiller
Affiliations
Meta-Analysis

Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease

Johanna Hummel et al. Cochrane Database Syst Rev. .

Abstract

Background: Low cardiac output syndrome remains a serious complication, and accounts for substantial morbidity and mortality in the postoperative course of paediatric patients undergoing surgery for congenital heart disease. Standard prophylactic and therapeutic strategies for low cardiac output syndrome are based mainly on catecholamines, which are effective drugs, but have considerable side effects. Levosimendan, a calcium sensitiser, enhances the myocardial function by generating more energy-efficient myocardial contractility than achieved via adrenergic stimulation with catecholamines. Thus potentially, levosimendan is a beneficial alternative to standard medication for the prevention of low cardiac output syndrome in paediatric patients after open heart surgery.

Objectives: To review the efficacy and safety of the postoperative prophylactic use of levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.

Search methods: We identified trials via systematic searches of CENTRAL, MEDLINE, Embase, and Web of Science, as well as clinical trial registries, in June 2016. Reference lists from primary studies and review articles were checked for additional references.

Selection criteria: We only included randomised controlled trials (RCT) in our analysis that compared prophylactic levosimendan with standard medication or placebo, in infants and children up to 18 years of age, who were undergoing surgery for congenital heart disease.

Data collection and analysis: Two review authors independently extracted data and assessed risk of bias according to a pre-defined protocol. We obtained additional information from all but one of the study authors of the included studies. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of evidence from the studies that contributed data to the meta-analyses for the prespecified outcomes. We created a 'Summary of findings' table to summarise the results and the quality of evidence for each outcome.

Main results: We included five randomised controlled trials with a total of 212 participants in the analyses. All included participants were under five years of age. Using GRADE, we assessed there was low-quality evidence for all analysed outcomes. We assessed high risk of performance and detection bias for two studies due to their unblinded setting. Levosimendan showed no clear effect on risk of mortality (risk ratio (RR) 0.47, 95% confidence interval (CI) 0.12 to 1.82; participants = 123; studies = 3) and no clear effect on low cardiac output syndrome (RR 0.64, 95% CI 0.39 to 1.04; participants = 83; studies = 2) compared to standard treatments. Data on time-to-death were not available from any of the included studies.There was no conclusive evidence on the effect of levosimendan on the secondary outcomes. The length of intensive care unit stays (mean difference (MD) 0.33 days, 95% CI -1.16 to 1.82; participants = 188; studies = 4), length of hospital stays (MD 0.26 days, 95% CI -3.50 to 4.03; participants = 75; studies = 2), duration of mechanical ventilation (MD -0.04 days, 95% CI -0.08 to 0.00; participants = 208; studies = 5), and the risk of mechanical circulatory support or cardiac transplantation (RR 1.49, 95% CI 0.19 to 11.37; participants = 60; studies = 2) did not clearly differ between the groups. Published data about adverse effects of levosimendan were limited. A meta-analysis of hypotension, one of the most feared side effects of levosimendan, was not feasible because of the heterogeneous expression of blood pressure values.

Authors' conclusions: The current level of evidence is insufficient to judge whether prophylactic levosimendan prevents low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease. So far, no significant differences have been detected between levosimendan and standard inotrope treatments in this setting.The authors evaluated the quality of evidence as low, using the GRADE approach. Reasons for downgrading were serious risk of bias (performance and detection bias due to unblinded setting of two RCTs), serious risk of inconsistency, and serious to very serious risk of imprecision (small number of included patients, low event rates).

PubMed Disclaimer

Conflict of interest statement

JH: None known.

GR: received payment for a one‐day course on statistical methods in meta‐analysis by Grünenthal Group, Aachen, Germany.

BS: None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Mortality, outcome: 1.1 Mortality.
5
5
Forest plot of comparison: 2 Low cardiac output syndrome (LCOS), outcome: 2.1 LCOS.
1.1
1.1. Analysis
Comparison 1 Mortality, Outcome 1 Mortality.
2.1
2.1. Analysis
Comparison 2 Low cardiac output syndrome (LCOS), Outcome 1 LCOS.
3.1
3.1. Analysis
Comparison 3 Length of ICU stay, Outcome 1 Length of ICU stay (days).
3.2
3.2. Analysis
Comparison 3 Length of ICU stay, Outcome 2 Length of ICU stay (days).
4.1
4.1. Analysis
Comparison 4 Length of hospital stay, Outcome 1 Length of hospital stay (days).
5.1
5.1. Analysis
Comparison 5 Duration of mechanical ventilation, Outcome 1 Duration of mechanical ventilation (days).
5.2
5.2. Analysis
Comparison 5 Duration of mechanical ventilation, Outcome 2 Duration of mechanical ventilation (days).
6.1
6.1. Analysis
Comparison 6 Mechanical circulatory support or cardiac transplantation, Outcome 1 Mechanical circulatory support or cardiac transplantation.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Ebade 2013 {published data only}
    1. Ebade A, Khalil M, Mohamed A. Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery. Journal of Anesthesia 2013;27(3):334–9. [DOI: 10.1007/s00540-012-1537-9] - DOI - PubMed
Lechner 2012 {published data only}
    1. Lechner E, Hofer A, Leitner‐Peneder G, Freynschlag R, Mair R, Weinzettel R, et al. Levosimendan versus milrinone in neonates and infants after corrective open‐heart surgery. Pediatric Critical Care Medicine 2012;13(5):542‐8. [DOI: 10.1097/PCC.0b013e3182455571] - DOI - PubMed
Momeni 2011 {published data only}
    1. Momeni M, Rubay J, Matta A, Rennotte M‐T, Veyckemans F, Poncelet A, et al. Levosimendan in congenital cardiac surgery: a randomized, double‐blind clinical trial. Journal of Cardiothoracic and Vascular Anesthesia 2011;25(3):419‐24. [DOI: 10.1053/j.jvca.2010.07.004] - DOI - PubMed
Pellicer 2013 {published data only}
    1. Pellicer A, Riera J, Lopez‐Ortego P, Bravo M, Madero R, Perez‐Rodriguez J, et al. Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery. Pediatric Research 2013;73(1):95‐103. [DOI: 10.1038/pr.2012.154] - DOI - PubMed
Ricci 2012 {published data only}
    1. Ricci Z, Garisto C, Favia I, Vitale V, Chiara L, Cogo P. Levosimendan infusion in newborns after corrective surgery for congenital heart disease: randomized controlled trial. Intensive Care Medicine 2012;38(7):1198‐204. [DOI: 10.1007/s00134-012-2564-6] - DOI - PubMed

References to studies excluded from this review

Bravo 2011 {published data only}
    1. Bravo MC, López P, Cabañas F, Perez‐Rodriguez J, Pérez‐Fernández E, Pellicer A. Acute effects of levosimendan on cerebral and systemic perfusion and oxygenation in newborns: an observational study. Neonatology 2011;99(3):217‐23. [DOI: 10.1159/000314955] - DOI - PubMed
Di Chiara 2010 {published data only}
    1. Chiara L, Ricci Z, Garisto C, Morelli S, Giorni C, Vitale V, et al. Initial experience with levosimendan infusion for preoperative management of hypoplastic left heart syndrome. Pediatric Cardiology 2010;31(1):166‐7. [DOI: 10.1007/s00246-009-9571-6] - DOI - PubMed
Egan 2006 {published data only}
    1. Egan J, Clarke A, Williams S, Cole A, Ayer J, Jacobe S, et al. Levosimendan for low cardiac output: a pediatric experience. Journal of Intensive Care Medicine 2006;21(3):183‐7. [DOI: 10.1177/0885066606287039] - DOI - PubMed
Giordano 2013 {published data only}
    1. Giordano R, Palma G, Palumbo S, Cioffi S, Russolillo V, Mucerino M, et al. Single center experience with levosimendan administration after pediatric cardiac surgery. Giornale Italiano di Cardiologia / Abstract del XLIII Congresso Nazionale SICP ‐ Sezione Pediatrica e delle Cardiopatie Congenite SICCH 2013;14(Suppl 1 AL N 10):35S‐6S.
Osthaus 2009 {published data only}
    1. Osthaus W, Boethig D, Winterhalter M, Huber D, Goerler H, Sasse M, et al. First experiences with intraoperative Levosimendan in pediatric cardiac surgery. European Journal of Pediatrics 2009;168(6):735‐40. [DOI: 10.1007/s00431-008-0834-7] - DOI - PubMed
Turanlahti 2004 {published data only}
    1. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatric Critical Care Medicine: A Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2004;5(5):457‐62. [DOI: 10.1097/01.PCC.0000137355.01277.9C] - DOI - PubMed

References to ongoing studies

EUCTR 2012‐005310‐19‐ES {unpublished data only}
    1. EUCTR 2012‐005310‐19‐ES. Double‐blind randomized clinical trial to evaluate the efficacy and safety of levosimendan as preischemic myocardial conditioner in pediatric cardiac surgery. www.clinicaltrialsregister.eu/ctr‐search/search?query=EUCTR2012‐005310‐1... (accessed 26 November 2014).

Additional references

Bailey 2004
    1. Bailey J, Hoffman T, Wessel D, Nelson D, Atz A, Chang A, et al. A population pharmacokinetic analysis of milrinone in pediatric patients after cardiac surgery. Journal of Pharmacokinetics and Pharmacodynamics 2004;31(1):43‐59. - PubMed
Baysal 2010
    1. Baysal A, Sasmazel A, Yildirim A, Kocak Tu, Sunar H, Zeybek R. The effects of thyroid hormones and interleukin‐8 levels on prognosis after congenital heart surgery. Archives of the Turkish Society of Cardiology 2010;38(8):537‐43. - PubMed
Braun 2004
    1. Braun J‐P, Schneider M, Kastrup M, Liu J. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. European Journal of Cardio‐thoracic Surgery 2004;26(1):228‐30. - PubMed
Burkhardt 2015
    1. Burkhardt B, Rücker G, Stiller B. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD009515.pub2] - DOI - PMC - PubMed
Butts 2012
    1. Butts R, Scheurer M, Atz A, Zyblewski S, Hulsey T, Bradley S. Comparison of maximum vasoactive inotropic score and low cardiac output syndrome as markers of early postoperative outcomes after neonatal cardiac surgery. Pediatric Cardiology 2012;33(4):633‐8. - PMC - PubMed
Dellinger 2013
    1. Dellinger R, Levy M, Rhodes A, Annane D, Gerlach H, Opal S. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Medicine 2013;39(2):165‐228. - PMC - PubMed
Elkayam 2007
    1. Elkayam U, Tasissa G, Binanay C, Stevenson L, Gheorghiade M, Warnica J, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. American Heart Journal 2007;153(1):98‐104. - PubMed
Endoh 2002
    1. Endoh M. Mechanisms of action of novel cardiotonic agents. Journal of Cardiovascular Pharmacology 2002;40(3):323‐38. - PubMed
Fernández 2012
    1. Fernández de Palencia‐Espinosa MA, Cárceles‐Barón MD, Blázquez‐Álvarez MJ, Arocas‐Casañ V, Rubia‐Nieto A. [Retrospective descriptive study about the use of levosimendan in children undergoing surgical correction for congenital heart disease]. Revista Española de Anestesiología y Reanimación 2012;59(9):489‐96. - PubMed
Follath 2002
    1. Follath F, Cleland J, Just H, Papp J, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low‐output heart failure (the LIDO study): a randomised double‐blind trial. Lancet 2002;360(9328):196‐202. - PubMed
Froese 2009
    1. Froese N, Sett S, Mock T, Krahn G. Does troponin‐I measurement predict low cardiac output syndrome following cardiac surgery in children?. Critical Care and Resuscitation 2009;11(2):116‐21. - PubMed
Graciano 2005
    1. Graciano A, Balko J, Rahn D, Ahmad N, Giroir B. The Pediatric Multiple Organ Dysfunction Score (P‐MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Critical Care Medicine 2005;33(7):1484‐91. - PubMed
GRADEpro GDT 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 16 June 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Harbord 2006
    1. Harbord R, Egger M, Sterne J. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443‐57. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hoffman 2003
    1. Hoffman T, Wernovsky G, Atz A, Kulik T, Nelson D, Chang A, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003;107(7):996‐1002. - PubMed
Hoffman 2011
    1. Hoffman T. Newer inotropes in pediatric heart failure. Journal of Cardiovascular Pharmacology 2011;58(2):121‐5. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lim 2015
    1. Lim J, Deo S, Rababa'h A, Altarabsheh S, Cho Y. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta‐analysis. Journal of Cardiac Surgery 2015;30(7):547‐54. - PubMed
Lobacheva 2010
    1. Lobacheva G, Khar'kin A, Manerova A, Dzhobava E. Intensive care for newborns and babies of the first year of life with acute heart failure after cardiosurgical interventions. Anesteziologiia i Reanimatologiia 2010;5:23‐7. - PubMed
Luca 2006
    1. Luca L, Colucci W, Nieminen M, Massie B, Gheorghiade M. Evidence‐based use of levosimendan in different clinical settings. European Heart Journal 2006;27(16):1908‐20. - PubMed
Ma 2007
    1. Ma M, Gauvreau K, Allan C, Mayer J, Jenkins K. Causes of death after congenital heart surgery. Annals of Thoracic Surgery 2007;83(4):1438‐45. - PubMed
Magliola 2009
    1. Magliola R, Moreno G, Vassallo J, Landry L, Althabe M, Balestrini M, et al. Levosimendan, a new inotropic drug: experience in children with acute heart failure [Levosimendán, un nuevo agente inotrópico:experiencia en niños con fallo cardíaco agudo]. Archivos Argentinos de Pediatria 2009;107(2):139‐45. - PubMed
Miera 2015
    1. Miera O, Daehnert I, Haas N, Hirt M, Thul J. Acute heart failure and ventricular assist device (VAD)/extracorporeal membrane oxygenation (ECMO) [Akute herzinsuffizienz und ventrikulärer assist device (VAD)/extrakorporale membranoxygenierung (ECMO)]. Available from www.kinderkardiologie.org/leitlinien/ (accessed 18 February 2015).
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. BMJ (Clinical research ed.) 2009;339:b2535. - PMC - PubMed
Moiseyev 2002
    1. Moiseyev V, Poder P, Andrejevs N, Ruda M, Golikov A, Lazebnik L, et al. Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo‐controlled, double‐blind study (RUSSLAN). European Heart Journal 2002;23(18):1422‐32. - PubMed
Namachivayam 2006
    1. Namachivayam P, Crossland D, Butt W, Shekerdemian L. Early experience with levosimendan in children with ventricular dysfunction. Pediatric Critical Care Medicine 2006;7(5):445‐8. - PubMed
Orion Pharma 2009
    1. Orion Pharma. Simdax ‐ Summary of product characteristics. Available from www.simdax.com/About‐Simdax/SPC/ (accessed 16 September 2014).
Overgaard 2008
    1. Overgaard C, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 2008;118(10):1047‐56. - PubMed
Packer 1993
    1. Packer M. The search for the ideal positive inotropic agent. New England Journal of Medicine 1993;329(3):201‐2. - PubMed
Papp 2005
    1. Papp Z, Csapo K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovascular Drug Reviews 2005;23(1):71‐98. - PubMed
Parr 1975
    1. Parr G, Blackstone E, Kirklin J. Cardiac performance and mortality early after intracardiac surgery in infants and young children. Circulation 1975;51(5):867‐74. - PubMed
R Development Core Team 2016 [Computer program]
    1. R Development Core Team. R: a language and environment for statistical computing. Version 3.3.2. Vienna, Austria: The R Foundation for Statistical Computing, 2016.
RevMan 5 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rücker 2011
    1. Rücker G, Schwarzer G, Carpenter J, Binder H, Schumacher M. Treatment‐effect estimates adjusted for small‐study effects via a limit meta‐analysis. Biostatistics 2011;12(1):122‐42. - PubMed
Samadi 2012
    1. Samadi M, Malaki M, Ghaffari S, Khalili R. Correlation between pediatric open heart surgery outcomes and arterial‐mixed venous oxygen saturation differences. Journal of Cardiovascular and Thoracic Research 2012;4(2):41‐4. - PMC - PubMed
Schulz 2005
    1. Schulz K, Grimes D. Sample size calculations in randomised trials: mandatory and mystical. Lancet 2005;365(9467):1348‐53. - PubMed
Shann 2003
    1. Shann F. Drug Doses. 12th Edition. Victoria: Royal Children’s Hospital, 2003.
Shi 2008
    1. Shi S, Zhao Z, Liu X, Shu Q, Tan L, Lin R, et al. Perioperative risk factors for prolonged mechanical ventilation following cardiac surgery in neonates and young infants. Chest 2008;134(4):768‐74. - PubMed
Silvetti 2015
    1. Silvetti S, Silvani P, Azzolini M, Dossi R, Landoni G, Zangrillo A. A systematic review on levosimendan in paediatric patients. Current Vascular Pharmacology 2015;13(1):128‐33. - PubMed
Stocker 2007
    1. Stocker C, Shekerdemian L, Norgaard M, Brizard C, Mynard J, Horton S, et al. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass. Critical Care Medicine 2007;35(1):252‐9. - PubMed
Vela 2012
    1. Vela J, Benitez J, Gonzalez M, Lopez M, Perez R, Meneses V, et al. Summary of the consensus document: clinical practice guide for the management of low cardiac output syndrome in the postoperative period of heart surgery. Medicina Intensiva/Sociedad Espanola de Medicina Intensiva y Unidades Coronarias 2012;36(4):277‐87. - PubMed
Verheugt 2008
    1. Verheugt C, Uiterwaal C, Grobbee D, Mulder B. Long‐term prognosis of congenital heart defects: a systematic review. International Journal of Cardiology 2008;131(1):25‐32. - PubMed
Vogt 2011
    1. Vogt W, Läer S. Treatment for paediatric low cardiac output syndrome: results from the European EuLoCOS‐Paed survey. Archives of Disease in Childhood 2011;96(12):1180‐6. - PubMed
Wernovsky 1995
    1. Wernovsky G, Wypij D, Jonas R, Mayer J, Hanley F, Hickey P, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low‐flow cardiopulmonary bypass and circulatory arrest. Circulation 1995;92(8):2226‐35. - PubMed

Publication types

MeSH terms

LinkOut - more resources